Prebiotics and probiotics: Their role in the management of gastrointestinal disorders in adults

Nutrition in Clinical Practice

Volumn 27, Issue 2, 2012, Pages 195-200

  Quigley, Eamonn M M ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

bifidobacteria; diarrhea; enteric infections; inflammatory bowel disease; intestinal flora; irritable bowel syndrome; lactobacilli; microbiota; prebiotics; probiotics

Indexed keywords

PREBIOTIC AGENT; PROBIOTIC AGENT; SYNBIOTIC AGENT;

ARTICLE; BACTERIAL GROWTH; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ENTERITIS; GASTROINTESTINAL DISEASE; HOST; HUMAN; INFECTIOUS DIARRHEA; INTESTINE FLORA; IRRITABLE COLON; NONHUMAN; TREATMENT OUTCOME;

ADULT; BACTERIA; DIARRHEA; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRACT; HUMANS; INFECTION; INFLAMMATORY BOWEL DISEASES; IRRITABLE BOWEL SYNDROME; PREBIOTICS; PROBIOTICS;

EID: 84859303007     PISSN: 08845336     EISSN: 19412452     Source Type: Journal    
DOI: 10.1177/0884533611423926     Document Type: Article

References (51)

1. Palmer C, Bik EM, DiGiulio DB, Relman DA, Brown PO. Development of the human infant intestinal microbiota. PloS Biol. 2007 ; 5: 1556-1573
2. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet. 2003 ; 361: 512-519
3. Neish AS. Microbes in gastrointestinal health and disease. Gastroenterology. 136: 65-80
4. Hattori M, Taylor TD. The human intestinal microbiome: a new frontier of human biology. DNA Res. 2009 ; 16: 1-12
5. Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science. 2005 ; 308: 1635-1638
6. Shanahan F. The host-microbe interface within the gut. Best Pract Res Clin Gastroenterol. 2002 ; 16: 915-931
7. O'Hara AM, Shanahan F. Gut microbiota: mining for therapeutic potential. Clin Gastroenterol Hepatol. 2007 ; 5: 274-284
8. Isolauri E, Salminen S, Ouwehand AC. Microbial-gut interactions in health and disease: probiotics. Best Pract Res Clin Gastroenterol. 2004 ; 18: 299-313
9. Kelly CP, LaMont JT. Clostridium difficile-more difficult than ever. N Engl J Med. 2008 ; 359: 1932-1940
10. Neu J, Mshvildadze M, Mai V. A roadmap for understanding and preventing necrotizing enterocolitis. Curr Gastroenterol Rep. 2008 ; 10: 450-457
11. Quigley EMM, Abu-Shanab A. The diagnosis of small intestinal bacterial overgrowth: the challenges persist!. Expert Rev Gastroenterol Hepatol. 2009 ; 3: 77-87
12. Sartor RB, Muehlbauer M. Microbial host interactions in IBD: implications for pathogenesis and therapy. Curr Gastroenterol Rep. 2007 ; 9: 497-507
13. Quigley EMM. Passing the bug-translocation, bacteraemia, and sepsis in the intensive care unit patient: is intestinal decontamination the answer?. Crit Care Med. 2011 ; 39: 1202-1203
14. Tilg H, Moschen AR, Kaser A. Obesity and the microbiota. Gastroenterology. 2009 ; 136: 1476-1483
15. Zhang H, DiBaise JK, Zuccolo A, et al. Human gut microbiota in obesity and after gastric bypass. Proc Natl Acad Sci U S A. 2009 ; 106: 2365-2370
16. Shanahan F. Probiotics: a perspective on problems and pitfalls. Scand J Gastroenterol. 2003 ; 38 (suppl). 34-36
17. EUR-lex. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX: 32006R1924R(01):EN:NOT. Accessed July 19, 2010.
18. O'Toole PW, Cooney JC. Probiotic bacteria influence the composition and function of the intestinal microbiota. Interdiscip Perpsect Infect Dis. 2008 ; 2008: 175285
19. Hibbing ME, Fuqua C, Parsek MR, Peterson SB. Bacterial competition: surviving in the microbial jungle. Nat Rev Microbiol. 2010 ; 8: 15-25
20. Preidis GA, Versalovic J. Targeting the human microbiome with antibiotics, probiotics and prebiotics: gastroenterology enters the metagenomics era. Gastroenterology. 2009 ; 136: 2015-2031
21. Quigley EMM. Microflora modulation of motility. J Neurogastroenterol Motil. 2011 ; 17: 140-147
22. Dunne C, Murphy L, Flynn S, et al. Probiotics: from myth to reality. Demonstration of functionality in animal models of disease and in human clinical trials. Antonie Van Leeuwenhoek. 1999 ; 76: 279-292
23. Michail S, Sylvester F, Fuchs G, Issenman R. Clinical efficacy of probiotics: review of the evidence with focus on children. J Pediatr Gastroenterol Nutr. 2006 ; 43: 550-557
24. Floch MH, Walker WA, Guandalini S, et al. Recommendations for probiotic use-2008. J Clin Gastroenterol. 2008 ; 42 (suppl 2). S104 - S108
25. Allen SJ, Okoko B, Martinez E, Gregorio G, Dans LF. Probiotics for treating infectious diarrhoea. Cochrane Database Syst Rev. 2004 ; ( 2 ):
26. D'Souza AL, Rajkumar CH, Cooke J, et al. Probiotics in prevention of antibiotic associated diarrhea: meta-analysis. BMJ. 2002 ; 324: 1361-1366
27. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol. 2006 ; 101: 812-822
28. Ewaschuk JB, Tejpar QZ, Soo I, Madsen K, Fedorak RN. The role of antibiotic and probiotic therapies in current and future management of inflammatory bowel disease. Curr Gastroenterol Rep. 2006 ; 8: 486-498
29. Gionchetti P, Rizzello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology. 2003 ; 124: 1202-1209
30. Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut. 2004 ; 53: 108-114
31. Hussein Z, Quigley EM. Complementary and alternative medicine in irritable bowel syndrome. Aliment Pharmacol Ther. 2006 ; 15: 465-471
32. Quigley EMM, Flourie B. Probiotics in irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date. Neurogastroenterol Motil. 2007 ; 19: 166-172
33. Nikfar S, Rahimi R, Rahimi F, Derakhshani S, Abdollahi M. Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials. Dis Colon Rectum. 2008 ; 51: 1775-1780
34. McFarland LV, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol. 2008 ; 14: 2650-2661
35. Hoveyda N, Heneghan C, Mahtani KR, Perera R, Roberts N, Glasziou P. A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol. 2009 ; 9: 15
36. Moayyedi P, Ford AC, Talley NJ, et al. The efficacy of probiotics in the therapy of irritable bowel syndrome: a systematic review. Gut. 2010 ; 59: 325-332
37. Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol. 2009 ; 104: 1033-1049
38. O'Mahony L, McCarthy J, Kelly P, et al. A randomized, placebo-controlled, double-blind comparison of the probiotic bacteria lactobacillus and bifidobacterium in irritable bowel syndrome (IBS): symptom responses and relationship to cytokine profiles. Gastroenterology. 2005 ; 128: 541-551
39. Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol. 2006 ; 101: 326-333
40. Boyle RJ, Robins-Browne RM, Tang MLK. Probiotic use in clinical practice: what are the risks?. Am J Clin Nutr. 2006 ; 83: 1256-1264
41. Kunz AN, Noel JM, Fairchok MP. Two cases of Lactobacillus bacteremia during probiotic treatment of short gut syndrome. J Pediatr Gastroenterol Nutr. 2004 ; 38: 457-458
42. DeGroote MA, Frank DN, Dowell E, Glode MP, Pace NR. Lactobacillus rhamnosus GG bacteremia associated with probiotic use in a child with short gut syndrome. Pediatr Infect Dis J. 2005 ; 24: 278-280
43. Besselink MG, van Santvoort HC, Buskens E, et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2008 ; 371: 651-659
44. Depeint F, Tzprtzis G, Vulevic J, L'anson K, Gibson GR. Prebiotic evaluation of a novel galactooligosaccharide mixture produced by the enzymatic activity of Bifidobacterium bifidum NCIMB 44171, in healthy humans: a randomized, double-blind, crossover, placebo-controlled intervention study. Am J Clin Nutr. 2008 ; 87: 785-791
45. Silk DBA, Davis A, Vulevic J, Tzortzis G, Gibson GR. Clinical trial: the effects of a trans-galactooligosaccharide on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther. 2009 ; 29: 508-518
46. Bouhnik Y, Neut C, Raskine L, et al. Prospective, randomized, parallel-group trial to evaluate the effects of lactulose and polyethylene glycol-4000 on colonic flora in chronic idiopathic constipation. Aliment Pharmacol Ther. 2004 ; 19: 889-899
47. Andriulli A, Neri M, Loguercio C, et al. Clinical trial on the efficacy of a new symbiotic formulation, Flortec, in patients with irritable bowel syndrome: a multicenter, randomized study. J Clin Gastroenterol. 2008 ; 42 (suppl 3, pt 2). S218 - S223
48. Colecchia A, Vestito A, La Rocca A, Pasqui F, Nikiforaki A, Festi D. Effect of a symbiotic preparation on the clinical manifestations of irritable bowel syndrome, constipation-variant: results of an open, uncontrolled multicenter study. Minerva Gastroenterol Dietol. 2006 ; 52: 349-358
49. Tsuchiya J, Barreto R, Okura R, et al. Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome. Chin J Dig Dis. 2004 ; 5: 169-174
50. Dughera L, Elia C, Navino M, Cisarò F. Effects of symbiotic preparations on constipated irritable bowel syndrome symptoms. Acta Biomed. 2007 ; 78: 111-116
51. Quigley EMM Probiotics in Pediatric Medicine. Michail S Sherman P, ed. Totowa, NJ: Humana ; 2008: 323-329.